BenzingaSeptember 30, 2026 at 12:22 PM NY27 Days Ago
BioMarin Pharmaceutical Inks License Deal With Ascendis Pharma; Grants Ascendis License For Transcon Cnp, Navepegritide, Yuviwel; Ascendis To Pay Biomarin 20% U.S., 18% EU/Br/Sk Royalty On Sales Until May 2030; All Pending Litigation Dismissed
https://www.sec.gov/ix?doc=/Archives/edgar/data/1048477/000162828026063981/bmrn-20260924.htm
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site: Benzinga
